Orchestra BioMed logo
Orchestra BioMed
OBIO | NASDAQ
Chart Builder DCF Calculator
$7.12
-$0.13 (-1.79%)
At close: Nov 16, 2026, 4:00 PM ET
$7.12
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Orchestra BioMed Company Profile

Company profile explained

Company Profile

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Key Executives

Name Position
David Hochman Founder, Chairman of the Board of Directors & Chief Executive Officer
Andrew Lawrence Taylor Chief Financial Officer
Darren R. Sherman Founder, President, Chief Operating Officer & Director
Yuval Hay Mika D.Sc GM & Chief Technology Officer of Bioelectronic Therapies
Avraham Matityahu Fischer Senior Vice President of Medical Affairs & Innovation
Bob Laughner Senior Vice President of Regulatory & Quality
Hans-Peter Stoll Senior Vice President & Medical Director
Juan Lorenzo Senior Vice President of Product Development
Lisa Daniels Vice President of Human Resources
William Reed Little Executive Vice President of Corporate Development & Strategy

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 01, 2026 8-K Current Report
Sep 11, 2026 4 Filing
Sep 08, 2026 8-K Current Report
Sep 08, 2026 4 Filing
Sep 02, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 14, 2026 4 Filing
View All SEC Filings ➞
Orchestra BioMed
Orchestra BioMed logo
Country United States
IPO Date Aug 4, 2020
Industry Biotechnology
Sector Healthcare
Employees 86
CEO David Hochman

Contact Details

150 Union Square Drive New Hope, Pennsylvania 18938 United States

Stock Details

Ticker Symbol OBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001814114
CUSIP Number 68572M106
ISIN Number US68572M1062
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.